<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6957133</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0227413</article-id><article-id pub-id-type="publisher-id">PONE-D-19-15279</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Rubella</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Infectious disease control</subject><subj-group><subject>Vaccines</subject><subj-group><subject>Viral vaccines</subject><subj-group><subject>MMR vaccine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral vaccines</subject><subj-group><subject>MMR vaccine</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Age Groups</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Togaviruses</subject><subj-group><subject>Rubella Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Togaviruses</subject><subj-group><subject>Rubella Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Togaviruses</subject><subj-group><subject>Rubella Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Togaviruses</subject><subj-group><subject>Rubella Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Europe</subject><subj-group><subject>Serbia</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Seroepidemiological study of rubella in Vojvodina, Serbia: 24 years after the introduction of the MMR vaccine in the national immunization programme</article-title><alt-title alt-title-type="running-head">Seroepidemiology of rubella</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7068-2882</contrib-id><name><surname>Pati&#x00107;</surname><given-names>Aleksandra</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>&#x00160;trbac</surname><given-names>Mirjana</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Petrovi&#x00107;</surname><given-names>Vladimir</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Milo&#x00161;evi&#x00107;</surname><given-names>Vesna</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6923-189X</contrib-id><name><surname>Risti&#x00107;</surname><given-names>Mioljub</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hrnjakovi&#x00107; Cvjetkovi&#x00107;</surname><given-names>Ivana</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Medi&#x00107;</surname><given-names>Sne&#x0017e;ana</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Centre for Virology, Institute of Public Health of Vojvodina, Novi Sad, Serbia</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Centre for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Chong</surname><given-names>Ka Chun</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>The Chinese University of Hong Kong, HONG KONG</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>aleksandra.patic@mf.uns.ac.rs</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><issue>1</issue><elocation-id>e0227413</elocation-id><history><date date-type="received"><day>29</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Pati&#x00107; et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Pati&#x00107; et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0227413.pdf"/><abstract><p>Although rubella is usually a mild childhood disease, this infection in early pregnancy poses a serious problem due to its teratogenic effect. The goal of interrupted circulation and elimination of rubella virus was achieved in many countries in the world. The aim of this study was to determine the status of rubella immunity in Vojvodina and evaluate Serbia&#x02019;s progress toward this goal. A total of 3404 residual serum samples from patients of all ages (1 to 84 years) were included in the study. Samples were collected between May 2015 and December 2017 in Vojvodina. Rubella IgG antibodies were determined using an indirect chemiluminescent immunoassay. Percentage of participants seropositive for rubella antibodies was 92.9% in the entire sample. The highest number of seronegatives was in the youngest (1 year) age group (44.7%), followed by the group aged 24&#x02013;49 (6.4%) and 2&#x02013;11 years (6.2%). The absence of a higher percentage of children with protective anti-rubella antibodies in the group aged 2&#x02013;11 can be explained by a lower immunization coverage during certain years. Participants in the group aged 24&#x02013;49 were born during the pre-vaccination period with lower rubella incidence, leading to the conclusion that not all individuals of that age came into a contact with the virus. Comparing levels of anti-rubella IgG antibodies of seropositive males and females of different ages reveals that the immunity after a contact with the virus and a previously acquired infection is stronger than the immunity after the vaccination. Although the incidence rate of rubella in Vojvodina has been low for the last ten years, there is still a risk of an outbreak due to a decrease in immunization coverage. This study shows that the percentage of susceptible individuals is high, especially considering women aged 24&#x02013;49, and that additional ("catch-up") immunization is required.</p></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Rubella is usually a mild childhood rash disease with rare complications. However, an infection in early pregnancy is of major public health importance due to the teratogenic effect of the virus. Primary infections during pregnancy may lead to miscarriage, fetal death, or a birth of an infant with congenital rubella syndrome (CRS). Infants with CRS may have sensorineural hearing loss, intellectual disability, heart defects, or ocular abnormalities. To address this issue, immunization against this disease has been introduced and control of CRS implemented [<xref rid="pone.0227413.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0227413.ref003" ref-type="bibr">3</xref>].</p><p>The Global Vaccine Action Plan for the Decade of Vaccines (2011&#x02013;2020), which was endorsed by the World Health Assembly in May 2012, has set an ambitious goal to achieve rubella elimination in at least five of the six WHO regions by 2020. The Region of the Americas has already eliminated rubella and CRS, as verified in 2015. The European Region and Western Pacific Region have set their own rubella and CRS elimination goals, while the South-East Asia Region has a target to control rubella and CRS [<xref rid="pone.0227413.ref004" ref-type="bibr">4</xref>]. A sustained vaccination coverage of 95% for at least one dose of the rubella-containing vaccine is recommended by the WHO to be implemented at all levels to interrupt the rubella circulation and achieve its elimination [<xref rid="pone.0227413.ref005" ref-type="bibr">5</xref>].</p><p>Rubella has been a mandatory notifiable disease in Serbia since 1976. Compulsory immunization of children against this disease became a part of the national immunization programme in 1993, and the MMR vaccine has been given in two doses since 1996. Immunization begins at 12 months, while the second dose of the vaccine was initially given at the age of 12. However, in 2006, the second dose was shifted to the age of seven, and the immunization at the age of 12 was continued only in children who had not received two doses of the MMR vaccine until then [<xref rid="pone.0227413.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0227413.ref007" ref-type="bibr">7</xref>].</p><p>The Programme of Health Protection of Citizens against Infectious Diseases determines the rubella prevention strategy in the Republic of Serbia. The goals of the programme are: maintaining a high level of coverage (&#x0003e;95%) with two doses of the MMR vaccine, supplemental immunization of the rubella-sensitive population, and the establishment and maintenance of the surveillance system with the aim of reducing the rate of congenital rubella syndrome to 0.01 per 1000 of live-born children [<xref rid="pone.0227413.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0227413.ref009" ref-type="bibr">9</xref>].</p><sec id="sec002"><title>Aim of the Study</title><p>The study was conducted to determine the status of rubella immunity in the population of the Autonomous Province of Vojvodina in order to identify susceptible groups in the population.</p></sec></sec><sec sec-type="materials|methods" id="sec003"><title>Materials and methods</title><sec id="sec004"><title>Study area and survey design</title><p>Vojvodina is the northern province of Serbia. The population of Vojvodina was 1,931,809 in 2011, accounting for 26.9% of the population of Serbia, excluding Kosovo [<xref rid="pone.0227413.ref010" ref-type="bibr">10</xref>]. Its borders are with Hungary to the north, Romania to the east, Croatia to the west, and Bosnia and Herzegovina to the southwest.</p><p>Notifications of the rubella disease are delivered to the Institute of Public Health of Vojvodina. The incidence rate of the disease was presented as the ratio of the number of patients and the whole population according to the census as the denominator per 100,000 inhabitants. The vaccine coverage of the MMR vaccine (the average value of the MMR1 and MMR2 coverage, as well as the individual coverage of MMR1 i MMR2) was calculated using the administrative method from 1993 to 2017 [<xref rid="pone.0227413.ref011" ref-type="bibr">11</xref>]. In our study we used data obtained from the official monthly and annual reports of the Institute of Public Health of Vojvodina in the period from 1978 to 2017. Data of incidence of rubella infection were presented through descriptive epidemiological study and analysed chronologically and demographically for the observed period (from 1978 to 2017).</p><p>Analysis of disease occurrence was performed during three separate periods. The first period is the endemoepidemic (sporadic combined with outbreak cases) period between 1978 and 1993. This is the pre-immunization period. The second one is the period of localized epidemics between 1993 and 2006. The vaccine against rubella was introduced in Serbia during this period, while the rubella infection occurred in the form of localized outbreaks affecting people in collectives. The third period is the period of sporadic cases, which began after 2006.</p><p>A total of 3404 residual serum samples from patients of all ages were included in the study. Samples were collected according to the specifications of the European Sero-Epidemiology Network 2 (ESEN2) study protocol between May 2015 and December 2017 in Vojvodina. The age stratification of the sera was according to the specifications of ESEN2. Accordingly, ~100 samples were collected for each year band in the age group 0&#x02013;19 years and ~200 samples for each of the age groups &#x02265;20 years (20&#x02013;24, 25&#x02013;29, 30&#x02013;34, 35&#x02013;39, 40&#x02013;49, 50&#x02013;59, and &#x02265;60), with about an equal number of samples by gender (sampling method has been described previously by Medi&#x00107;, et al. [<xref rid="pone.0227413.ref012" ref-type="bibr">12</xref>]).</p><p>For further analysis, the samples were divided into five age groups (1 year, 2&#x02013;11 years, 12&#x02013;23 years, 24&#x02013;49 years, and 50+ years). The age distribution was adjusted according to the periods of time, used for analyses of the disease occurrence. The age distribution was created after the samples were collected and results of the serum analyses were obtained. Available information for each patient included the following: sex, age, area of residence in Vojvodina, and sample collection date. Written informed consent of study participants, or their parents or legal guardians if they were &#x0003c;15 years of age, was obtained.</p></sec><sec id="sec005"><title>Determination of IgG antibodies for rubella virus</title><p>Serum samples were analysed in the Centre for Virology of the Institute of Public Health of Vojvodina, where the serological diagnostics were performed. The ADVIA Centaur Rubella IgG assay (Siemens Healthcare Diagnostics) was used for detection of rubella IgG antibodies. This immunoassay uses chemiluminometric technology. A direct relationship exists between the amount of rubella IgG activity present in the patient sample and the amount of relative light units (RLUs) detected by the system. Testing was performed on Siemens ADVIA Centaur automated analyser. As recommended by the manufacturer, all samples with anti-rubella IgG titres below 5.0 IU/mL were considered negative (susceptible to rubella). Values greater than or equal to 5.0 IU/mL, and less than or equal to 9.9 IU/mL, were considered equivocal (unknown rubella immunity status), while samples greater than or equal to 10.0 IU/mL were considered positive for IgG antibodies to rubella virus (protected against rubella). These values are based on the test manufacturer&#x02019;s recommendations (Siemens Healthcare Diagnostics, Tarrytown, NY, USA) [<xref rid="pone.0227413.ref013" ref-type="bibr">13</xref>].</p></sec><sec id="sec006"><title>Statistical analysis</title><p>Statistical analysis of the results was performed using the Statistical Software Package for the Social Sciences&#x02014;SPSS 21. Attributive features are shown as frequencies, percentages, and 95% confidence intervals. In order to investigate the connection of features, or to generate adequate statistical models, a univariate regression analysis was used. Binary Logistic Regression Analysis was used to generate odds ratios and confidence intervals. The testing of differences in the frequency of attribute characteristics was performed using the X<sup>2</sup> test. A two-factor ANOVA analysis was used to simultaneously test the effect of each independent variable on the dependent variable, also identifying a potential impact of their interaction. The Bonferroni post-hoc test was used for correction for multiple comparisons. Values with a significance level of p &#x0003c;0.05 were considered statistically significant.</p></sec><sec id="sec007"><title>Ethical consideration</title><p>The study was approved by the Medical Ethics Committee of the Institute of Public Health of Vojvodina, on 14th May 2015 under the number 01-79/7a, as a part of a wider serosurvey on vaccine-preventable diseases in Vojvodina.</p></sec></sec><sec sec-type="results" id="sec008"><title>Results</title><p>During the first period (pre-immunization period) in Vojvodina, rubella occurred endemoepidemically with a cyclic increase in incidence, reaching the values of over 1,000 per 100,000 inhabitants in epidemic years. The highest incidence rate of 1,402.1 per 100,000 inhabitants was reported in 1989.</p><p>The second period is marked by the introduction of the vaccine against rubella, while the rubella infection occurred in epidemic form, and the disease was registered with a declining trend until 2005. The highest incidence rate of 939.1 and 653.6 per 100,000 inhabitants was reported in 1995 and 1994, respectively, while the lowest coverage of the MMR vaccine (82%) was registered in 2000.</p><p>The third period began in 2006, when no cases were reported for the first time, while only sporadic cases per year were registered in 2009, 2012, and 2015. Since 2012, there has been a declining trend in the MMR vaccine coverage in the territory of Vojvodina, with the lowest coverage registered in 2017 (78%). (<xref ref-type="fig" rid="pone.0227413.g001">Fig 1</xref>, <xref ref-type="supplementary-material" rid="pone.0227413.s001">S1 Table</xref>).</p><fig id="pone.0227413.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227413.g001</object-id><label>Fig 1</label><caption><title>The incidence of rubella in Vojvodina between 1978 and 2017, and the average of MMR1 and MMR2 vaccination coverage between 1993 and 2017.</title></caption><graphic xlink:href="pone.0227413.g001"/></fig><p>In this study of population immunity against rubella virus in Vojvodina, 3404 serum samples were analysed. The age of examined patients ranged from 1 to 84 years. Among participants included in the study, there were 1652 females and 1752 males. Immunocompromised individuals and recent recipients of blood and blood products were excluded. The percentage of participants seropositive for rubella antibodies was 92.9% (95% Cl, 92.0&#x02013;93.8%) in the entire sample. There were 194 individuals (5.7%) without antibodies against rubella, while 1.4% of the participants had borderline values.</p><p>The values of rubella seropositivity for males and females were 92.5% and 93.3%, respectively. Although a higher proportion of seropositivity was found in females compared to males, the difference was not statistically significant (p = 0.291).</p><p>The highest number of seronegativity was found in the youngest (1 year) participant group (44.7%), followed by the age group of 24&#x02013;49 years (6.4%) and the group of children aged 2&#x02013;11 years (6.2%). Although the participants in the age group of 24&#x02013;49 years were born during the pre-vaccination period, they have a slightly higher seronegativity (6.4%) compared to the group of &#x02265;50 years. This difference is statistically significant (x<sup>2</sup> = 20.973; p &#x0003c;0.001). The percentage of equivocal results in both females and males in the age groups of 1 year and 12&#x02013;23 years ranged between 2.2 and 4.0%, while the percentage in the other age groups ranged between 0.4% and 1.2% (<xref rid="pone.0227413.t001" ref-type="table">Table 1</xref>).</p><table-wrap id="pone.0227413.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227413.t001</object-id><label>Table 1</label><caption><title>Seroprevalence of anti-rubella antibodies according to the age and gender in Vojvodina, Serbia, 2015&#x02013;2017.</title></caption><alternatives><graphic id="pone.0227413.t001g" xlink:href="pone.0227413.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1"/><th align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">Seropositive</th><th align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">Seronegative</th><th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">Equivocal</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Total</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/></tr><tr><th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">Age group</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">%<break/>(95%CI)</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">%<break/>(95%CI)</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">%<break/>(95%CI)</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">OR<break/>(95%CI)</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="center" rowspan="6" style="background-color:#FFFFFF" colspan="1">Males</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">44</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">48.4<break/>(38.1&#x02013;58.7)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">45</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">49.5<break/>(39.2&#x02013;59.8)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2.2<break/>(0.8&#x02013;5.2)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">91</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">250.0<break/>(31.0&#x02013;1717.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2-11y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">438</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">93.8<break/>(91.6&#x02013;95.9)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">25</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">5.4<break/>(3.4&#x02013;7.4)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">4</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.9<break/>(0.0&#x02013;1.8)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">467</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">13.3<break/>(1.8&#x02013;99.1)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.011</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">12-23y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">484</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">95.8<break/>(94.1&#x02013;97.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">8</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.6<break/>(0.5&#x02013;2.7)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">13</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2.6<break/>(1.2&#x02013;4.0)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">505</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">3.8<break/>(0.5&#x02013;30.5)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.210</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">24-49y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">420</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">92.9<break/>(90.5&#x02013;95.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">28</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6.2<break/>(4.0&#x02013;8.4)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">4</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.9<break/>(0.0&#x02013;1.8)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">452</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">15.6<break/>(2.1&#x02013;115.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.007</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x02265;50y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">235</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">99.2<break/>(98.1&#x02013;100.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.4<break/>(-0.4&#x02013;1.2)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.4<break/>(-0.4&#x02013;1.2)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">237</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.0<xref ref-type="table-fn" rid="t001fn001">*</xref></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Total</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,621</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">92.5<break/>(91.3&#x02013;93.7)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">107</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6.1<break/>(5.0&#x02013;7.2)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">24</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.4<break/>(0.8&#x02013;2.0)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,752</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="6" style="background-color:#FFFFFF" colspan="1">Females</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">30</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">60<break/>(46.4&#x02013;73.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">18</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">36<break/>(22.7&#x02013;49.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">4.0<break/>(1.4&#x02013;9.4)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">50</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">33.3<break/>(10.7&#x02013;105.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2-11y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">361</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">91.9<break/>(89.2&#x02013;94.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">28</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">7.1<break/>(4.6&#x02013;9.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">4</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.0<break/>(0.0&#x02013;2.0)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">393</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">4.6<break/>(1.6&#x02013;13.2)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.005</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">12-23y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">499</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">96.3<break/>(94.67&#x02013;97.9)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">7</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.4<break/>(0.4&#x02013;2.4)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">12</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2.3<break/>(1.0&#x02013;3.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">518</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.8<break/>(0.2&#x02013;2.8)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.751</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">24-49y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">416</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">92.9<break/>(90.5&#x02013;95.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">30</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6.7<break/>(4.4&#x02013;9.0)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.4<break/>(0.2&#x02013;1.0)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">448</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">142.9<break/>(1.5&#x02013;12.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.007</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x02265;50y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">236</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">97.1<break/>(94.9&#x02013;99,2)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">4</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.6<break/>(0.0&#x02013;3.2)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">3</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.2<break/>(0.2&#x02013;2.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">243</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.0<xref ref-type="table-fn" rid="t001fn001">*</xref></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Total</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,542</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">93.3<break/>(92.1&#x02013;94.5)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">87</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">5.3<break/>(4.2&#x02013;6.4)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">23</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.4<break/>(0.8&#x02013;2.0)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,652</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="6" style="background-color:#FFFFFF;border-bottom:thick" colspan="1">Total</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">74</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">52.5<break/>(44.3&#x02013;60.7)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">63</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">44.7<break/>(36.5&#x02013;52.9)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">4</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2.8<break/>(0.1&#x02013;5.5)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">141</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">76.7<break/>(29.9&#x02013;196.7)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2-11y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">799</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">92.9<break/>(91.2&#x02013;94.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">53</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6.2<break/>(4.6&#x02013;7.8)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">8</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.9<break/>(0.3&#x02013;1.5)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">860</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6.2<break/>(2.5&#x02013;15.7)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">12-23y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">983</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">96.1<break/>(94.9&#x02013;97.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">15</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.5<break/>(0.8&#x02013;2.2)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">25</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2.4<break/>(1.5&#x02013;3.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,023</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.4<break/>(0.5&#x02013;3.9)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.505</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">24-49y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">836</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">92.9<break/>(91.2&#x02013;94.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">58</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6.4<break/>(4.8&#x02013;8.0)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.7<break/>(0.2&#x02013;1.2)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">900</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6.5<break/>(2.6&#x02013;16.4)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x02265;50y</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">471</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">98.1<break/>(96.9&#x02013;99.3)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">5</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.0<break/>(0.1&#x02013;1.9)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">4</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.8<break/>(0.0&#x02013;1.6)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">480</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.0<xref ref-type="table-fn" rid="t001fn001">*</xref></td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/></tr><tr><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">Total</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">3,163</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">92.9<break/>(92.0&#x02013;93.8)</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">194</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">5.7<break/>(4.9&#x02013;6.5)</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">47</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">1.4<break/>(1.0&#x02013;1.8)</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">3,404</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>*Reference value</p></fn><fn id="t001fn002"><p>OR&#x02013;Odds Ratio; CI&#x02014;Confidence Interval; p&#x02013;probability</p></fn><fn id="t001fn003"><p>Binary Logistic Regression Analysis was used to generate odds ratios and confidence intervals.</p></fn></table-wrap-foot></table-wrap><p>In the entire sample, using the age group of &#x02265;50 years as a comparator, the prevalence of rubella seronegative results was significantly higher in the following age groups: 1 year, 2&#x02013;11 years, and adults aged 24&#x02013;49 years (OR 76.73, OR 6.24, and OR 6.54, respectively). Similar results are obtained in the same age groups for males and females. The results are shown in <xref rid="pone.0227413.t001" ref-type="table">Table 1</xref>.</p><p>Analysing the percentage of seropositive subjects in the three observed periods, we found that there were statistically significantly fewer seropositives in the age group of &#x0003c;11 years compared to the other two observed age groups (x<sup>2</sup> = 71,910; p &#x0003c;0.001) (<xref rid="pone.0227413.t002" ref-type="table">Table 2</xref>).</p><table-wrap id="pone.0227413.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227413.t002</object-id><label>Table 2</label><caption><title>Percentage of seropositive and seronegative according to the age groups.</title></caption><alternatives><graphic id="pone.0227413.t002g" xlink:href="pone.0227413.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="3" style="background-color:#FFFFFF;border-top:thick"/><th align="center" colspan="8" style="background-color:#FFFFFF;border-top:thick" rowspan="1">Age group</th><th align="center" rowspan="3" style="background-color:#FFFFFF;border-top:thick" colspan="1">p</th></tr><tr><th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">&#x02264;11</th><th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">12&#x02013;23</th><th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">24+</th><th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">Total</th></tr><tr><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">N</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">%</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">N</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">%</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">N</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">%</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">N</th><th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="3" style="background-color:#FFFFFF;border-bottom:thick" colspan="1">Rubella CLIA IgG results</td><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Seronegative</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">128</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">12,8%</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">40</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">3,9%</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">73</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">5,3%</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">241</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">7,1%</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Seropositive</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">873</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">87,2%</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">983</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">96,1%</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.307</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">94,7%</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">3.163</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">92,9%</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">Total</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">1.001</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">100,0%</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">1.023</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">100,0%</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">1.380</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">100,0%</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">3.404</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">100,0%</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>p&#x02013;probability; X<sup>2</sup> test was used to determine whether there is a statistically significant difference in the percentage of seropositives during the three observed periods.</p></fn></table-wrap-foot></table-wrap><p>Comparing the levels of anti-rubella IgG antibodies across these three periods, we found that in the period of single cases of the rubella disease, the lowest levels of antibodies were found in the 1-year old participants compared to the age group of 2&#x02013;11 years old. The highest levels of IgG antibodies were detected in the age group older than 24 years, which belongs to the period of massive epidemics of the rubella infection.</p><p>In the age group of 12&#x02013;23 years, which belongs to the period of localized epidemics of the rubella infection and the introduction of the MMR vaccine in the population of Vojvodina, the levels of antibodies were low for both males and females compared to the other age groups (<xref ref-type="fig" rid="pone.0227413.g002">Fig 2</xref> and <xref ref-type="fig" rid="pone.0227413.g003">Fig 3</xref>).</p><fig id="pone.0227413.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227413.g002</object-id><label>Fig 2</label><caption><title>Serum level of anti-rubella IgG in seropositive females.</title></caption><graphic xlink:href="pone.0227413.g002"/></fig><fig id="pone.0227413.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227413.g003</object-id><label>Fig 3</label><caption><title>Serum level of anti-rubella IgG in seropositive males.</title></caption><graphic xlink:href="pone.0227413.g003"/></fig><p>Also, we analysed whether there was a statistically significant difference in measured antibody levels in different age groups (during the three observed periods) in seropositive subjects. The analysis showed that there was a statistically significant difference in antibody levels compared to the observed age groups (ANOVA; F = 99,394; p &#x0003c;0.001). The Bonferroni post hoc test showed that patients aged 12&#x02013;23 years had statistically significantly lower antibody levels compared to those aged &#x0003c;11 years (p &#x0003c;0.001), as well as those aged 24+ years (p &#x0003c;0.001). Patients older than 24 years (there is no difference between the age group of 24&#x02013;49 years and those older than 50) also had statistically significantly higher antibody levels compared to those younger than 11 years (p&#x0003c;0.001). Patients from the oldest age group had statistically significantly higher antibody levels than subjects aged 12&#x02013;23 years (p &#x0003c;0.001) (<xref rid="pone.0227413.t003" ref-type="table">Table 3</xref>, <xref ref-type="supplementary-material" rid="pone.0227413.s002">S1 Fig</xref>).</p><table-wrap id="pone.0227413.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227413.t003</object-id><label>Table 3</label><caption><title>Antibody levels in different age groups (during the three observed periods) in seropositive participants.</title></caption><alternatives><graphic id="pone.0227413.t003g" xlink:href="pone.0227413.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1"/><th align="center" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1">N</th><th align="center" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1">Mean</th><th align="center" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1">Std. Deviation</th><th align="center" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1&#x02013;11</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">711</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">152,9883</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">118,66190</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">12&#x02013;23</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">926</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">108,1632</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">102,87936</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">24+</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">890</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">185,4685</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">129,72264</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">Total</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">2.527<xref ref-type="table-fn" rid="t003fn001">*</xref></td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">148,0019</td><td align="center" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">121,81713</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>* Samples that had antibody level values greater than 500 IU/ml were not included in this analysis, since we did not have an accurate antibody level value for them. The assay we used can determine antibody level values only up to 500 IU/ml.</p></fn><fn id="t003fn002"><p>The two-way ANOVA analysis and the Bonferroni post hoc test were used to determine whether there is a statistically significant difference in the antibody levels in seropositive participants during the three observed periods.</p></fn></table-wrap-foot></table-wrap><p>We further tested the effect of gender and age groups on antibody levels, as shown in the <xref rid="pone.0227413.t004" ref-type="table">Table 4</xref>. Using the Two-way ANOVA analysis, we tested the individual effect of gender and age groups, as well as a potential impact of their interaction, on antibody levels. The effect of gender and age group interaction on antibody levels was not statistically significant (F = 0.359; p = 0.698). There was a statistically significant individual effect of age groups (subjects&#x02019; age) on antibody levels (F = 99,472; p&#x0003c;0.001), but no individual effect of subjects&#x02019; gender (F = 0.981; p = 0.322).</p><table-wrap id="pone.0227413.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227413.t004</object-id><label>Table 4</label><caption><title>Influence of gender and age on serum level of anti-rubella IgG in seropositive participants.</title></caption><alternatives><graphic id="pone.0227413.t004g" xlink:href="pone.0227413.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1">gender</th><th align="left" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1">Age group (years)</th><th align="center" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1">Mean</th><th align="center" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1">Std. Deviation</th><th align="center" style="background-color:#FFFFFF;border-top:thick" rowspan="1" colspan="1">N</th></tr></thead><tbody><tr><td align="left" rowspan="4" style="background-color:#FFFFFF" colspan="1">male</td><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1&#x02013;11</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">148,2071</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">118,01142</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">388</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">12&#x02013;23</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">107,4753</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">104,88812</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">454</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">24+</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">184,4087</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">127,10503</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">445</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Total</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">146,3559</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">121,16096</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.287</td></tr><tr><td align="left" rowspan="4" style="background-color:#FFFFFF" colspan="1">female</td><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1&#x02013;11</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">158,7317</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">119,36821</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">323</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">12&#x02013;23</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">108,8248</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">101,01651</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">472</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">24+</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">186,5283</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">132,42313</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">445</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Total</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">149,7103</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">122,51995</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.240</td></tr><tr><td align="left" rowspan="4" style="background-color:#FFFFFF;border-bottom:thick" colspan="1">Total</td><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1&#x02013;11</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">152,9883</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">118,66190</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">711</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">12&#x02013;23</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">108,1632</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">102,87936</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">926</td></tr><tr><td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">24+</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">185,4685</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">129,72264</td><td align="right" style="background-color:#FFFFFF" rowspan="1" colspan="1">890</td></tr><tr><td align="left" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">Total</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">148,0019</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">121,81713</td><td align="right" style="background-color:#FFFFFF;border-bottom:thick" rowspan="1" colspan="1">2.527</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>The two-way ANOVA analysis was used to determine whether there is a statistically significant influence of gender and age on antibody levels in seropositive participants during the three observed periods.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions" id="sec009"><title>Discussion</title><p>According to the latest reports, epidemiological situation of rubella in most EU countries is favourable. In 2017, 11 European countries reported 696 rubella cases, which represented a marked decrease from 1,264 and 2,161 cases reported in 2016 and 2015, respectively. During 2017, in the territory of 17 European countries there were no rubella cases. The highest number of cases was reported in Poland (496, where the last epidemic was registered), Germany (73), Italy (67), and Austria (39) [<xref rid="pone.0227413.ref004" ref-type="bibr">4</xref>]. In 2016, six cases of CRS were reported in 42 European countries which keep records and report this syndrome [<xref rid="pone.0227413.ref014" ref-type="bibr">14</xref>].</p><p>During the ten-year period (2008&#x02013;2017), only three cases of rubella infection were reported (in 2009, in 2012, and in 2015). The reservoir of infection in all three cases was not determined. Therefore, the actual number of cases might have been higher [<xref rid="pone.0227413.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0227413.ref007" ref-type="bibr">7</xref>].</p><p>In this study, the percentage of participants seropositive for rubella antibodies was 92.9% in the entire sample. This percentage of seropositivity is similar to the percentage obtained in a study in Luxembourg in 2004 [<xref rid="pone.0227413.ref015" ref-type="bibr">15</xref>], but lower than the percentage obtained in Hungary, Slovenia, and Slovakia, and higher than the one found in Romania and Bulgaria in 2008 [<xref rid="pone.0227413.ref016" ref-type="bibr">16</xref>]. A higher percentage of seropositives in Hungary, Slovenia, and Slovakia can be explained by a &#x0003e;95% coverage of the MMR vaccine in these countries, but also by a previously acquired immunity of the population following a natural infection. [<xref rid="pone.0227413.ref017" ref-type="bibr">17</xref>].</p><p>In contrast to our study, in the study conducted in Vojvodina between 1978 and 1984 on a sample of 1,550 individuals aged from six months to 60 years, the percentage of susceptible individuals aged &#x02265;20 years ranged from 0% to 15% [<xref rid="pone.0227413.ref018" ref-type="bibr">18</xref>]. The period of research in this study belongs to the pre-vaccination era. In our study, the percentage of susceptible individuals in the group aged &#x02265;20 years was 4.2% (6.4% in the age group of 24&#x02013;49 years, and 1% in the age group of &#x02265;50 years). These data only confirm that the introduction of the MMR vaccine has significantly reduced the number of susceptible individuals in the Vojvodina population. Despite the high percentage of people with protective anti-rubella IgG antibodies, the number of susceptible individuals is still higher than recommended (&#x0003c;5%) by the World Health Organization. The goal of rubella and CRS elimination can only be achieved when the population susceptibility is below the level that can sustain transmission. Thus, a population immunity of at least 95% is recommended to interrupt the transmission and eliminate rubella. Susceptibility should be lower than 5% especially in children and women of generative age [<xref rid="pone.0227413.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0227413.ref019" ref-type="bibr">19</xref>].</p><p>In our study, the highest number of seronegatives is found in the youngest (1 year) age group, followed by the age group of 24&#x02013;49 years, and the group of children aged 2&#x02013;11 years.</p><p>A lower percentage of seropositive participants in the group of children aged 1 year (52.5%) can be explained by the fact that a portion of the subjects in this group have lost protective maternal antibodies but have not yet received the first dose of the MMR vaccine. The level of antibodies transferred from mother to child shows an exponentially declining trend, resulting in the loss of protection against rubella after a few months&#x02013;well before the age of the first MMR vaccine dose [<xref rid="pone.0227413.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0227413.ref021" ref-type="bibr">21</xref>]. The first dose of the MMR vaccine, which should be administered between 12 and 15 months of age, is often received later and, therefore, children aged 1 year have no protective antibodies. A similar result was obtained in a study conducted in Turkey, where the percentage of seropositives in the group of children aged 1&#x02013;2 years was 51.9% [<xref rid="pone.0227413.ref022" ref-type="bibr">22</xref>]. In a study conducted in Germany on a representative sample of children under 17, it was determined that the percentage of seropositives in children aged 1&#x02013;2 years was 69.3% [<xref rid="pone.0227413.ref023" ref-type="bibr">23</xref>].</p><p>In our study, the percentage of seropositives in children aged 2&#x02013;11 years was 92.9%. The absence of a higher percentage of children with protective anti-rubella antibodies in this group can be explained by a lower immunization coverage of the MMR vaccine during certain years in the period from 2006 to 2017. Immunization coverage on the territory of Vojvodina was lower than 95% in 2012 (91%), 2014 (86%), 2015 (90%), 2016 (89%), and 2017 (78%). Decreasing immunization trend in Vojvodina can be explained by a reduction in timely availability of the MMR vaccine in Serbia from 2012&#x02013;2016, as well as an increased activity and media presence of the anti-vaccination movement in the Balkan countries, which has contributed to a surge in vaccine scepticism and vaccine hesitancy [<xref rid="pone.0227413.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0227413.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0227413.ref025" ref-type="bibr">25</xref>]. Maintaining such a negative trend in immunization coverage leads to an increase in the number of susceptible populations. This creates conditions for the importation and spread of the disease which was previously successfully prevented by immunization. Due to this situation, there was a measles epidemic outbreak in Vojvodina from November 12, 2017 to June 30, 2018, during which 177 cases were reported [<xref rid="pone.0227413.ref024" ref-type="bibr">24</xref>]. There has been no increase in notification of rubella cases in Vojvodina. That happened probably because, if one dose of the MMR vaccine was higher in coverage than the other in a given year, there is a possibility that a certain level of antibodies was created, because one of MMR doses had higher coverage and there is a likelihood that more children received at least one dose of the vaccine. This means that, although there may be a lower level of antibodies in certain age groups, it seems to be sufficient to prevent the outbreak of rubella virus epidemics in the population, which was not the case with measles. In a study conducted in the northern part of Greece, the percentage of seropositives in children aged 6&#x02013;10 years (71.8%) and 11&#x02013;15 years (77.1%) was significantly lower than the percentage obtained in our study [<xref rid="pone.0227413.ref026" ref-type="bibr">26</xref>]. A lower percentage of seropositives was also found in a study in Germany, with the result of 82.2% in children aged 3&#x02013;6 years, and 80.6% in children aged 7&#x02013;10 years [<xref rid="pone.0227413.ref023" ref-type="bibr">23</xref>].</p><p>Although the participants in the age group of 24&#x02013;49 years were born during the pre-vaccination period, they have a slightly higher seronegativity (6.4%) compared to the group of &#x02265;50 years. This difference is statistically significant (x<sup>2</sup> = 20.973; p &#x0003c;0.001). A possible explanation can be found in the registered incidence of less than 100 per 100,000 inhabitants in Vojvodina in certain years during the period after 1986, which leads to the conclusion that not all individuals of that age came into a contact with the virus. This finding underlines the need for a vaccination strategy targeting older people as well, especially women of generative age [<xref rid="pone.0227413.ref019" ref-type="bibr">19</xref>]. Our results are quite different from those obtained in a study carried out in Italy, where the percentage of seropositive women of generative age (18&#x02013;49 years) was only 82.3% [<xref rid="pone.0227413.ref027" ref-type="bibr">27</xref>]. Much better results were obtained in a study in the Netherlands [<xref rid="pone.0227413.ref028" ref-type="bibr">28</xref>] and in part of Spain&#x02014;Catalonia [<xref rid="pone.0227413.ref029" ref-type="bibr">29</xref>], which found &#x0003e;95% of seropositive women of generative age.</p><p>A low number of seronegatives was also found among the participants aged 12&#x02013;23 years (1.5%). Individuals in this age group were born between 1993 and 2005. The introduction of the second dose of the MMR vaccine into Serbia&#x02019;s immunization schedule in 1996 increased the likelihood of children receiving at least one dose of the vaccine and thus acquiring vaccine immunity. Also, the introduction of the anti-rubella vaccine was suppressed by an intense rubella infection in the population during the 1994&#x02013;1995 epidemics, when more than 32,000 people were infected. Therefore, in this period, it was possible to obtain immunity from a rubella infection. A higher percentage in the age group of 16&#x02013;20 years (8.7%) was obtained in a study conducted in the northern part of Greece [<xref rid="pone.0227413.ref026" ref-type="bibr">26</xref>].</p><p>The lowest number of seronegative participants was found in the group aged 50+ (1.0%). People from this age group were born before routine vaccination against rubella. In the pre-vaccination era, the average annual incidence of rubella was high. A large number of people could have come into a contact with the rubella virus as early as childhood and more frequently in older age, and therefore, were more likely to have acquired immunity from a natural infection.</p><p>Comparing levels of anti-rubella IgG antibodies of seropositive males and females of different ages reveals that those born before 1993 generally show statistically significantly higher levels of rubella-specific IgG antibodies compared to those born during the period when the MMR vaccination was introduced. This is consistent with the fact that the immunity after a contact with the rubella virus and a previously acquired infection is stronger than the immunity which develops after the vaccination. These results are consistent with the results obtained by Smits G. et al, in the Netherlands study [<xref rid="pone.0227413.ref028" ref-type="bibr">28</xref>].</p><p>Individuals born between 1993 and 2006 (aged 12&#x02013;23 years) have statistically significantly lower levels of anti-rubella IgG antibodies. During this period, the MMR vaccine immunization programme was introduced and the vaccination schedule changed. Introduction of the vaccine against rubella limited the circulation of the virus in the population. However, the coverage of the vaccination in this period was lower than required, so it is possible that many individuals did not receive both doses of the MMR vaccine. Consequently, the anti-rubella IgG antibody levels &#x0200b;&#x0200b;are lower. This is confirmed by the study by Pebody RG. et al, who highlighted that the geometric mean antibody concentration of rubella was significantly higher in children who have received a second dose of the MMR compared to those who have received a single dose [<xref rid="pone.0227413.ref030" ref-type="bibr">30</xref>]. Also, in this age group there was a higher percentage of equivocal results. It is very likely that vaccine immunity has declined among these individuals because they have not received both doses of the vaccine. Consequently, it is not only individuals with equivocal test results who present a problem in this age group. After some time, the problem may also be with individuals who currently have sufficient levels of protective antibodies, but&#x02013;due to the possible administration of only one dose of the MMR vaccine&#x02013;might experience a more rapid decrease in antibody levels.</p><p>In children born after 2006, the lowest antibody level was among those aged 1 year. Most children in that age group have lost maternal antibodies, so their existing antibodies are the result of a single dose of the MMR vaccine. Although children are expected to develop normal antibody titres in response to the initial MMR dose, some children develop low antibody levels to all three antigens in the MMR vaccine, and some (the non-responders) develop no antibodies. Low antibody levels may be caused by a small proportion of complete vaccination failures, impotent vaccine, incorrect delivery, or individual factors related to an underdeveloped immune system [<xref rid="pone.0227413.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0227413.ref031" ref-type="bibr">31</xref>]. In the group of children aged 2&#x02013;11 years, the level of anti-rubella IgG antibodies was higher since many of them have received both doses of the MMR vaccine.</p><p>Our study might have some limitations. First, for the duration of the study, the number of samples of the youngest participants was slightly lower than planned. The study used serum samples of patients from routine work, from which a serum bank was made to test the immunity of the population to certain pathogens (measles, varicella, hepatitis A, hepatitis B and rubella). Due to the analyses done for all these agents, we had 26% less serum in the age group of 1 year for the purposes of our research on the immunity to rubella virus. Regarding the OR result for the 1y group, we understand that the OR number is high, but we can try to explain. The &#x0003e;50y age group was taken as a reference value for comparisons. This age group belongs to the unvaccinated population which has witnessed high incidence rates of rubella during major epidemics. Of the 237 subjects over the age of 50, only one male subject was seronegative, and one male subject had an equivocal finding. As many as 99.2% were seropositive, so the OR for male subjects aged 1 was 250, and its confidence intervals were wide, which could potentially limit the ability for adequate interpretation of the results. Second, equivocal results were not retested in terms of a definitive laboratory classification (positive or negative). Third, standardization was not performed due to a lack of a reference (comparative) panel. For epidemiological purposes, the enzyme immunoassay (EIA) is a widely used method to detect antibodies to rubella in serum. However, variations in both sensitivity and specificity of several commercial EIAs have been reported, as well as inter-laboratory variability when the same assay is used. Therefore, the European Sero-Epidemiology Network recommends standardization of assays to ensure direct comparability of seroepidemiology results obtained during different projects. Fourth, we did not collect individual immunization coverage of participants, migrant status, education level and other personal data. Therefore, we could only guess whether specific anti-rubella IgG antibodies originated from vaccination or natural infection. However, that was not the initial idea of the study. This was the first study on the immunity of the Vojvodina population to rubella virus. Some future research could provide additional data. Fifth, it is quite possible that the population-level immunity to rubella virus may be lower than the results obtained in this study, since immunocompromised individuals were excluded. For that reason, we think that further research is needed in the future, which we are planning to do. The collected serums were from Vojvodina residents who came to our institution for laboratory testing during the study period. Subjects' participation in the study was voluntary. The study included the subjects who gave their written informed consent to participate in the study. It is possible that some refused to participate because they avoided vaccination (either for themselves or for their children), but we do not currently have information about it.</p></sec><sec sec-type="conclusions" id="sec010"><title>Conclusion</title><p>Seroepidemiological study in the population of Vojvodina shows that the percentage of susceptible individuals is higher than 5%, which leads us to suspect that there is an increased risk of the rubella disease, which is especially dangerous in women aged 24&#x02013;49. Although the incidence rate of rubella in Vojvodina has been continuously below 1 per 100,000 for the last ten years, due to the percent of seronegative individuals in our investigation as well as obvious decrease in the coverage of the MMR vaccine, there is still a risk of a potential outbreak as well as a possible occurrence of congenital rubella syndrome in newborns.</p><p>The highest levels of IgG antibodies among seropositive participants were detected in the age group older than 24 years, which belongs to the period of massive epidemics of the rubella disease, indicating that natural acquired immunity results in a higher level of antibodies compared to subjects who have acquired immunity with the vaccine.</p><p>It is important to identify susceptible populations, and, in parallel with high coverage of two doses of the MMR vaccine in children, perform additional vaccination of seronegative individuals, especially seronegative women of generative age ("catch-up" campaign) in order to avoid risk of rubella infections in the future.</p></sec><sec sec-type="supplementary-material" id="sec011"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0227413.s001"><label>S1 Table</label><caption><title>The incidence of rubella in Vojvodina between 1978 and 2017, and the individual coverage of MMR1 i MMR2 vaccine between 1993 and 2017.</title><p>(DOC)</p></caption><media xlink:href="pone.0227413.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0227413.s002"><label>S1 Fig</label><caption><title>Serum level of anti-rubella IgG in different age groups (during the three observed periods) in seropositive participants.</title><p>(TIF)</p></caption><media xlink:href="pone.0227413.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors are grateful to all employees of the Centre for Virology and Centre for Disease Control and Prevention of the Institute of Public Health of Vojvodina (Novi Sad, Serbia) for their contribution to this study. A special thanks goes to Zoran Topalov (Institute of Public Health of Vojvodina, Novi Sad, Serbia) for valuable advice in processing and statistical analysis of data.</p></ack><ref-list><title>References</title><ref id="pone.0227413.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Cooper</surname><given-names>LZ</given-names></name>. <article-title>The history and medical consequences of rubella</article-title>. <source>Rev Infect Dis</source>
<year>1985</year>; <volume>7</volume>(<issue>Suppl 1</issue>):<fpage>2</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1093/clinids/7.Supplement_1.S2</pub-id>
<?supplied-pmid 3890105?><pub-id pub-id-type="pmid">3890105</pub-id></mixed-citation></ref><ref id="pone.0227413.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Miller</surname><given-names>E</given-names></name>, <name><surname>Cradock-Watson</surname><given-names>JE</given-names></name>, <name><surname>Pollock</surname><given-names>TM</given-names></name>. <article-title>Consequences of confirmed maternal rubella at successive stages of pregnancy</article-title>. <source>Lancet</source>. <year>1982</year>;<volume>2</volume>(<issue>8302</issue>):<fpage>781</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(82)92677-0</pub-id>
<?supplied-pmid 6126663?><pub-id pub-id-type="pmid">6126663</pub-id></mixed-citation></ref><ref id="pone.0227413.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>N</given-names></name>, <name><surname>Strebel</surname><given-names>P</given-names></name>, <name><surname>Orenstein</surname><given-names>W</given-names></name>, <name><surname>Icenogle</surname><given-names>J</given-names></name>, <name><surname>Poland</surname><given-names>GA</given-names></name>. <source>Rubella. Lancet</source>. <year>2015</year>; <volume>385</volume>(<issue>9984</issue>):<fpage>2297</fpage>&#x02013;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60539-0</pub-id>
<?supplied-pmid 25576992?><pub-id pub-id-type="pmid">25576992</pub-id></mixed-citation></ref><ref id="pone.0227413.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Grant</surname><given-names>GB</given-names></name>, <name><surname>Reef</surname><given-names>SE</given-names></name>, <name><surname>Patel</surname><given-names>M</given-names></name>, <name><surname>Knapp</surname><given-names>JK</given-names></name>, <name><surname>Dabbagh</surname><given-names>A</given-names></name>. <article-title>Progress in Rubella and Congenital Rubella Syndrome Control and Elimination&#x02014;Worldwide, 2000&#x02013;2016</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2017</year>; <volume>66</volume>(<issue>45</issue>):<fpage>1256</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm6645a4</pub-id>
<?supplied-pmid 29145358?><pub-id pub-id-type="pmid">29145358</pub-id></mixed-citation></ref><ref id="pone.0227413.ref005"><label>5</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <source>Eliminating measles and rubella&#x02014;Framework for the verification process in the WHO European Region [Internet]</source>. <publisher-loc>Copenhagen</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>2014</year> [accessed 2019 March 9]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.euro.who.int/__data/assets/pdf_file/0009/247356/Eliminating-measles-and-rubella-Framework-for-the-verification-process-in-the-WHO-European-Region.pdf?ua=1">http://www.euro.who.int/__data/assets/pdf_file/0009/247356/Eliminating-measles-and-rubella-Framework-for-the-verification-process-in-the-WHO-European-Region.pdf?ua=1</ext-link></mixed-citation></ref><ref id="pone.0227413.ref006"><label>6</label><mixed-citation publication-type="other">Institute of Public Health of Vojvodina. [Communicable diseases in Vojvodina, 2017. Annual report]. Novi Sad: Institute of Public Health of Vojvodina; 2018. Serbian.</mixed-citation></ref><ref id="pone.0227413.ref007"><label>7</label><mixed-citation publication-type="other">&#x00160;eguljev Z. Rubeola. U: Petrovi&#x00107; V, urednik. Imunizacija protiv zaraznih bolesti. Novi Sad: Medicinski fakultet; 2015. p. 115&#x02013;120. Serbian.</mixed-citation></ref><ref id="pone.0227413.ref008"><label>8</label><mixed-citation publication-type="other">Institute of Public Health of Serbia. Guideline for epidemiological surveillance of Measles, Rubella and Congenital Rubella Syndrome. Belgrade. 2008. Serbian.</mixed-citation></ref><ref id="pone.0227413.ref009"><label>9</label><mixed-citation publication-type="other">Official Gazette of the Republic of Serbia No. 88/02017. Regulation on Immunization and Manner of Protection by Medications. [accessed 2019 January 15]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.paragraf.rs/propisi/pravilnik_o_imunizaciji_i_nacinu_zastite_lekovima.html">http://www.paragraf.rs/propisi/pravilnik_o_imunizaciji_i_nacinu_zastite_lekovima.html</ext-link>. Serbian.</mixed-citation></ref><ref id="pone.0227413.ref010"><label>10</label><mixed-citation publication-type="other">Statistical Office of the Republic of Serbia. 2011 Census of Population, Households and Dwellings in the Republic of Serbia. [accessed 2019 January 15]. Available from: <ext-link ext-link-type="uri" xlink:href="http://pod2.stat.gov.rs/ObjavljenePublikacije/Popis2011/Nacionalna%20pripadnost-Ethnicity.pdf">http://pod2.stat.gov.rs/ObjavljenePublikacije/Popis2011/Nacionalna%20pripadnost-Ethnicity.pdf</ext-link>. Serbian/English.</mixed-citation></ref><ref id="pone.0227413.ref011"><label>11</label><mixed-citation publication-type="other">World Health Organization. Immunization coverage. Department for Vaccines and Biologicals, Immunization, Surveillance and Monitoring System. [accessed 2019 March 9]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/">https://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/</ext-link></mixed-citation></ref><ref id="pone.0227413.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Medi&#x00107;</surname><given-names>S</given-names></name>, <name><surname>Katsilieris</surname><given-names>M</given-names></name>, <name><surname>Lozanov-Crvenkovi&#x00107;</surname><given-names>Z</given-names></name>, <name><surname>Siettos</surname><given-names>CI</given-names></name>, <name><surname>Petrovi&#x00107;</surname><given-names>V</given-names></name>, <name><surname>Milo&#x00161;evi&#x00107;</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Varicella zoster virus transmission dynamics in Vojvodina, Serbia</article-title>. <source>PLoS One</source>. <year>2018</year>;<volume>13</volume>(<issue>3</issue>):<fpage>e0193838</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0193838</pub-id>
<?supplied-pmid 29505590?><pub-id pub-id-type="pmid">29505590</pub-id></mixed-citation></ref><ref id="pone.0227413.ref013"><label>13</label><mixed-citation publication-type="book"><collab>Siemens Healthcare Diagnostics</collab>. <source>Assay for the Detection of IgG Antibodies to Rubella Virus</source>. <publisher-loc>Tarrytown, NY</publisher-loc>: <publisher-name>Siemens Healthcare Diagnostics</publisher-name>
<year>2012</year>.</mixed-citation></ref><ref id="pone.0227413.ref014"><label>14</label><mixed-citation publication-type="book"><collab>European Centre for Disease Prevention and Control</collab>. <source>Monthly measles and rubella monitoring report, September 2018</source>. <publisher-loc>Stockholm</publisher-loc>: <publisher-name>ECDC</publisher-name>; <year>2018</year>.</mixed-citation></ref><ref id="pone.0227413.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Mossong</surname><given-names>J</given-names></name>, <name><surname>Putz</surname><given-names>L</given-names></name>, <name><surname>Schneider</surname><given-names>F</given-names></name>. <article-title>Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study</article-title>. <source>Epidemiol Infect</source>. <year>2004</year>;<volume>132</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1017/s0950268803001584</pub-id>
<?supplied-pmid 14979584?><pub-id pub-id-type="pmid">14979584</pub-id></mixed-citation></ref><ref id="pone.0227413.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Nardone</surname><given-names>A</given-names></name>, <name><surname>Tischer</surname><given-names>A</given-names></name>, <name><surname>Andrews</surname><given-names>N</given-names></name>, <name><surname>Backhouse</surname><given-names>J</given-names></name>, <name><surname>Theeten</surname><given-names>H</given-names></name>, <name><surname>Gatcheva</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets</article-title>. <source>Bull World Health Organ</source>. <year>2008</year>;<volume>86</volume>(<issue>2</issue>):<fpage>118</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.07.042010</pub-id>
<?supplied-pmid 18297166?><pub-id pub-id-type="pmid">18297166</pub-id></mixed-citation></ref><ref id="pone.0227413.ref017"><label>17</label><mixed-citation publication-type="other">WHO Europe. Measles and rubella elimination country profiles. [accessed 2019 January 15]; Available from: <ext-link ext-link-type="uri" xlink:href="http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-and-immunization/publications/surveillance-and-data/measles-and-rubella-elimination-country-profiles">http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-and-immunization/publications/surveillance-and-data/measles-and-rubella-elimination-country-profiles</ext-link></mixed-citation></ref><ref id="pone.0227413.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>&#x00110;uri&#x00161;i&#x00107;</surname><given-names>S</given-names></name>, <name><surname>Vukovi&#x00107;</surname><given-names>B</given-names></name>, <name><surname>Stefanovi&#x00107;</surname><given-names>S</given-names></name>, <name><surname>&#x00160;eguljev</surname><given-names>Z</given-names></name>, <name><surname>Milo&#x00161;evi&#x00107;</surname><given-names>V</given-names></name>. <article-title>Rubela u Vojvodini (Deo V) Distribucija i vrednost titra HI-antitela za rubela-virus u osoba razli&#x0010d;itih dobnih grupa</article-title>. <source>Med. Pregl</source>. <year>1988</year>;<volume>41</volume>(<issue>7&#x02013;8</issue>):<fpage>292</fpage>&#x02013;<lpage>5</lpage>. Serbian. <?supplied-pmid 3246978?><pub-id pub-id-type="pmid">3246978</pub-id></mixed-citation></ref><ref id="pone.0227413.ref019"><label>19</label><mixed-citation publication-type="book"><collab>WHO</collab>. <source>Strategic plan for measles and congenital rubella infection in the European Region of WHO</source>. <publisher-loc>Copenhagen</publisher-loc>: <publisher-name>WHO Regional Office for Europe</publisher-name>; <year>2003</year>.</mixed-citation></ref><ref id="pone.0227413.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Waaijenborg</surname><given-names>S</given-names></name>, <name><surname>Hahn&#x000e9;</surname><given-names>SJ</given-names></name>, <name><surname>Mollema</surname><given-names>L</given-names></name>, <name><surname>Smits</surname><given-names>GP</given-names></name>, <name><surname>Berbers</surname><given-names>GA</given-names></name>, <name><surname>van der Klis</surname><given-names>FR</given-names></name>, <etal>et al</etal>
<article-title>Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage</article-title>. <source>J Infect Dis</source>. <year>2013</year>
<month>7</month>;<volume>208</volume>(<issue>1</issue>):<fpage>10</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit143</pub-id>
<?supplied-pmid 23661802?><pub-id pub-id-type="pmid">23661802</pub-id></mixed-citation></ref><ref id="pone.0227413.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Nicoara</surname><given-names>C</given-names></name>, <name><surname>Z&#x000e4;ch</surname><given-names>K</given-names></name>, <name><surname>Trachsel</surname><given-names>D</given-names></name>, <name><surname>Germann</surname><given-names>D</given-names></name>, <name><surname>Matter</surname><given-names>L</given-names></name>. <article-title>Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses</article-title>. <source>Clin Diagn Lab Immunol</source>. <year>1999</year>;<volume>6</volume>(<issue>6</issue>):<fpage>868</fpage>&#x02013;<lpage>71</lpage>. <?supplied-pmid 10548578?><pub-id pub-id-type="pmid">10548578</pub-id></mixed-citation></ref><ref id="pone.0227413.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Kurug&#x000f6;l</surname><given-names>Z</given-names></name>, <name><surname>Midyat</surname><given-names>L</given-names></name>, <name><surname>T&#x000fc;rko&#x0011f;lu</surname><given-names>E</given-names></name>, <name><surname>Ozacar</surname><given-names>T</given-names></name>. <article-title>Rubella seroprevalence among healthy individuals in Izmir, Turkey</article-title>. <source>Hum Vaccin</source>. <year>2011</year>;<volume>7</volume>(<issue>9</issue>):<fpage>972</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.4161/hv.7.9.16370</pub-id>
<?supplied-pmid 21860258?><pub-id pub-id-type="pmid">21860258</pub-id></mixed-citation></ref><ref id="pone.0227413.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Poethko-M&#x000fc;ller</surname><given-names>C</given-names></name>, <name><surname>Mankertz</surname><given-names>A</given-names></name>. <article-title>Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>8</issue>):<fpage>e42867</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0042867</pub-id>
<?supplied-pmid 22880124?><pub-id pub-id-type="pmid">22880124</pub-id></mixed-citation></ref><ref id="pone.0227413.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Risti&#x00107;</surname><given-names>M</given-names></name>, <name><surname>Milo&#x00161;evi&#x00107;</surname><given-names>V</given-names></name>, <name><surname>Medi&#x00107;</surname><given-names>S</given-names></name>, <name><surname>Djeki&#x00107; Malba&#x00161;a</surname><given-names>J</given-names></name>, <name><surname>Raj&#x0010d;evi&#x00107;</surname><given-names>S</given-names></name>, <name><surname>Boban</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Sero-epidemiological study in prediction of the risk groups for measles outbreaks in Vojvodina, Serbia</article-title>. <source>PLoS One</source>. <year>2019</year>;<volume>14</volume>(<issue>5</issue>):<fpage>e0216219</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0216219</pub-id> .<?supplied-pmid 31071124?><pub-id pub-id-type="pmid">31071124</pub-id></mixed-citation></ref><ref id="pone.0227413.ref025"><label>25</label><mixed-citation publication-type="other">Institute of Public Health of Serbia &#x0201c;Dr Milan Jovanovic Batut&#x0201d;. Report on the Immunization in the Republic of Serbia in 2017. [Accessed 2019 October 15]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.batut.org.rs/download/izvestaji/Godisnji%20izvestaj%20imunizacija%202017.pdf">http://www.batut.org.rs/download/izvestaji/Godisnji%20izvestaj%20imunizacija%202017.pdf</ext-link> Serbian.</mixed-citation></ref><ref id="pone.0227413.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Gioula</surname><given-names>G</given-names></name>, <name><surname>Diza-Mataftsi</surname><given-names>E</given-names></name>, <name><surname>Alexiou-Daniel</surname><given-names>S</given-names></name>, <name><surname>Kyriazopoulou-Dalaina</surname><given-names>V</given-names></name>. <article-title>Seroepidemiology of rubella in northern Greece</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. <year>2004</year>;<volume>23</volume>(<issue>8</issue>):<fpage>631</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1007/s10096-004-1172-y</pub-id>
<?supplied-pmid 15243817?><pub-id pub-id-type="pmid">15243817</pub-id></mixed-citation></ref><ref id="pone.0227413.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Gallone</surname><given-names>MS</given-names></name>, <name><surname>Gallone</surname><given-names>MF</given-names></name>, <name><surname>Larocca</surname><given-names>AMV</given-names></name>, <name><surname>Germinario</surname><given-names>C</given-names></name>, <name><surname>Tafuri</surname><given-names>S</given-names></name>. <article-title>Lack of immunity against rubella among Italian young adults</article-title>. <source>BMC Infect Dis</source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>199</fpage>
<pub-id pub-id-type="doi">10.1186/s12879-017-2295-y</pub-id>
<?supplied-pmid 28270106?><pub-id pub-id-type="pmid">28270106</pub-id></mixed-citation></ref><ref id="pone.0227413.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Smits</surname><given-names>G</given-names></name>, <name><surname>Mollema</surname><given-names>L</given-names></name>, <name><surname>Hahn&#x000e9;</surname><given-names>S</given-names></name>, <name><surname>de Melker</surname><given-names>H</given-names></name>, <name><surname>Tcherniaeva</surname><given-names>I</given-names></name>, <name><surname>van der Klis</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Seroprevalence of rubella antibodies in The Netherlands after 32 years of high vaccination coverage</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>16</issue>):<fpage>1890</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.01.066</pub-id>
<?supplied-pmid 24513012?><pub-id pub-id-type="pmid">24513012</pub-id></mixed-citation></ref><ref id="pone.0227413.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Plans</surname><given-names>P</given-names></name>, <name><surname>de Ory</surname><given-names>F</given-names></name>, <name><surname>Campins</surname><given-names>M</given-names></name>, <name><surname>&#x000c1;lvarez</surname><given-names>E</given-names></name>, <name><surname>Pay&#x000e0;</surname><given-names>T</given-names></name>, <name><surname>Guisasola</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. <year>2015</year>;<volume>34</volume>(<issue>6</issue>):<fpage>1161</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/s10096-015-2339-4</pub-id>
<?supplied-pmid 25666082?><pub-id pub-id-type="pmid">25666082</pub-id></mixed-citation></ref><ref id="pone.0227413.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Pebody</surname><given-names>RG</given-names></name>, <name><surname>Gay</surname><given-names>NJ</given-names></name>, <name><surname>Hesketh</surname><given-names>LM</given-names></name>, <name><surname>Vyse</surname><given-names>A</given-names></name>, <name><surname>Morgan-Capner</surname><given-names>P</given-names></name>, <name><surname>Brown</surname><given-names>DW</given-names></name>, <etal>et al</etal>
<article-title>Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance</article-title>. <source>Vaccine</source>. <year>2002</year>;<volume>20</volume>(<issue>7&#x02013;8</issue>):<fpage>1134</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/s0264-410x(01)00435-2</pub-id>
<?supplied-pmid 11803074?><pub-id pub-id-type="pmid">11803074</pub-id></mixed-citation></ref><ref id="pone.0227413.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Herrera</surname><given-names>OR</given-names></name>, <name><surname>Thornton</surname><given-names>TA</given-names></name>, <name><surname>Helms</surname><given-names>RA</given-names></name>, <name><surname>Foster</surname><given-names>SL</given-names></name>. <article-title>MMR Vaccine: When Is the Right Time for the Second Dose?</article-title>. <source>J Pediatr Pharmacol Ther</source>. <year>2015</year>;<volume>20</volume>(<issue>2</issue>):<fpage>144</fpage>&#x02013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.5863/1551-6776-20.2.144</pub-id>
<?supplied-pmid 25964732?><pub-id pub-id-type="pmid">25964732</pub-id></mixed-citation></ref></ref-list></back></article>